Active Ingredient History
Tremelimumab is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Bile Duct Neoplasms (Phase 1/Phase 2)
Biliary Tract Neoplasms (Phase 2)
BRCA1 Protein (Phase 2)
Breast Neoplasms (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Merkel Cell (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Pancreatic Ductal (Phase 1)
Carcinoma, Renal Cell (Phase 3)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 3)
Cholangiocarcinoma (Phase 2)
Colorectal Neoplasms (Phase 2)
Digestive System Diseases (Phase 1)
Drugs, Investigational (Phase 2)
Dysgerminoma (Phase 2)
Endometrial Neoplasms (Phase 2)
Esophageal Neoplasms (Phase 2)
Esophageal Squamous Cell Carcinoma (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Fibrosis (Phase 2)
Gallbladder Neoplasms (Phase 2)
Genital Neoplasms, Female (Phase 1)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Hematologic Neoplasms (Phase 1/Phase 2)
Hepatitis C, Chronic (Phase 2)
HIV (Phase 2)
Hormones (Phase 2)
Hydronephrosis (Early Phase 1)
Hypertension, Portal (Phase 2)
Hypopharynx (Phase 2)
Immunotherapy (Phase 2)
Kidney Neoplasms (Phase 1/Phase 2)
Larynx (Phase 2)
Lip (Phase 1)
Liver Neoplasms (Phase 1/Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, B-Cell (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 1)
Lymphoma, T-Cell, Cutaneous (Phase 1/Phase 2)
Melanoma (Phase 3)
Menopause (Phase 2)
Mesothelioma (Phase 2)
Mesothelioma, Malignant (Phase 2)
Microsatellite Instability (Phase 2)
Mouth Neoplasms (Phase 1)
Multiple Myeloma (Phase 1)
Multiple Sclerosis (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroendocrine Tumors (Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Oropharynx (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 2)
Papillomavirus Infections (Phase 2)
Peritoneal Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Rare Diseases (Phase 2)
Sarcoma (Phase 2)
Seminoma (Phase 2)
Sepsis (Phase 1)
Small Cell Lung Carcinoma (Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 3)
Stomach Neoplasms (Phase 2)
Testicular Neoplasms (Phase 1/Phase 2)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 2)
Ureteral Neoplasms (Phase 1)
Urethral Neoplasms (Phase 1)
Urinary Bladder Diseases (Phase 2)
Urinary Bladder Neoplasms (Phase 3)
Uterine Cervical Neoplasms (Phase 1/Phase 2)
Vaginal Neoplasms (Phase 1)
Vulvar Neoplasms (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue